October 24, interim report
July – September 2024
Alligator hosted a webinar on Thursday, October 24, at 3 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the Q3 interim report, which was followed by a Q&A session.
The call was held in English, and can be requested below.
LATEST NEWS
Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update
Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 …
Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrate …
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024
Lund, Sweden and Seattle, Washington, September 13, 2024 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) …